Boston Scientific’s (BSX) Outperform Rating Reaffirmed at Royal Bank Of Canada

Royal Bank Of Canada reiterated their outperform rating on shares of Boston Scientific (NYSE:BSX) in a report published on Monday,Benzinga reports. Royal Bank Of Canada currently has a $115.00 price objective on the medical equipment provider’s stock.

Several other brokerages also recently commented on BSX. Needham & Company LLC reaffirmed a “buy” rating and set a $97.00 price objective on shares of Boston Scientific in a research note on Monday. Jefferies Financial Group reaffirmed a “buy” rating on shares of Boston Scientific in a research report on Monday, March 16th. The Goldman Sachs Group decreased their target price on shares of Boston Scientific from $98.00 to $93.00 and set a “buy” rating for the company in a research report on Friday. JPMorgan Chase & Co. lowered their price target on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Finally, Sanford C. Bernstein restated an “outperform” rating and set a $112.00 price objective on shares of Boston Scientific in a research note on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average price target of $104.36.

Boston Scientific Stock Down 9.1%

Shares of NYSE BSX opened at $62.90 on Monday. Boston Scientific has a 52-week low of $61.24 and a 52-week high of $109.50. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The stock has a market cap of $93.49 billion, a P/E ratio of 32.42, a P/E/G ratio of 1.07 and a beta of 0.69. The firm has a 50 day moving average price of $76.94 and a 200 day moving average price of $90.32.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period last year, the business posted $0.70 earnings per share. The business’s revenue for the quarter was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts expect that Boston Scientific will post 2.85 EPS for the current year.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of BSX. Brighton Jones LLC increased its stake in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares during the last quarter. Scotia Capital Inc. boosted its position in Boston Scientific by 0.7% during the 2nd quarter. Scotia Capital Inc. now owns 15,093 shares of the medical equipment provider’s stock worth $1,621,000 after buying an additional 104 shares during the period. VestGen Advisors LLC boosted its position in Boston Scientific by 116.1% during the 2nd quarter. VestGen Advisors LLC now owns 17,974 shares of the medical equipment provider’s stock worth $1,929,000 after buying an additional 9,656 shares during the period. Virtus Advisers LLC bought a new stake in Boston Scientific during the 2nd quarter worth approximately $157,000. Finally, Fisher Asset Management LLC increased its position in Boston Scientific by 13.9% in the 2nd quarter. Fisher Asset Management LLC now owns 7,705,384 shares of the medical equipment provider’s stock valued at $827,635,000 after acquiring an additional 939,834 shares during the period. Institutional investors own 89.07% of the company’s stock.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: FDA clearance for the Asurys fluid management system gives Boston Scientific another regulatory win and supports growth in perioperative/OR product offerings. Boston Scientific wins FDA clearance for fluid management system
• Positive Sentiment: Strong HI-PEITHO trial results for the EKOS endovascular system (positive readout reported) bolster the company’s pulmonary embolism franchise and provide clinical momentum for EKOS adoption. Boston Scientific Reports Strong HI-PEITHO Trial Results for EKOS
• Positive Sentiment: Several analysts reaffirm buy/outperform ratings and high price targets (Needham, TD Cowen, RBC), reflecting confidence in long-term growth drivers like Watchman FLX and diversified product mix. Buy Rating on Boston Scientific’s Watchman FLX
• Neutral Sentiment: Company set an investors’ conference call for the Q1 2026 results (April 22), which will be a key event for management to clarify guidance, procedure trends and margin outlook. Boston Scientific announces conference call
• Neutral Sentiment: Analysts expect single-digit EPS growth for Q1 2026; Q1 results and any guidance update will likely drive near-term volatility but may not change the long-term thesis. Boston Scientific’s Q1 2026 Earnings: What to Expect
• Negative Sentiment: Mixed/underwhelming clinical data for the Watchman device (conflicting trial readouts) is the proximate trigger for today’s sell-off as investors reprice stroke-prevention growth expectations. Boston Scientific Falls After Underwhelming Trial Results
• Negative Sentiment: Raymond James downgraded BSX and cut its price target, and Goldman trimmed its target as well — analyst downgrades and lower PTs pressured sentiment and valuation multiples. Shares Plunge After Raymond James Downgrade
• Negative Sentiment: Heightened legal/regulatory overhang — multiple investor alerts and class-action filings tied to prior disclosures are creating uncertainty and may keep pressure on the stock until resolved. BSX Investor Alert: Securities Fraud Lawsuit

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.